{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000086","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.920897+00:00","generated_at":"2026-06-01T04:05:52.704565+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025","bullets":["Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.","Heavily pretreated population: median 4 prior therapies (96.8% BTKi, 90.3% BCL2i, 25.8% non-covalent BTKi).","43.3% had BTK mutations, 20% PLCG2 mutations, 46.7% TP53 mutations; CNS involvement in 2 patients responded.","NX-5948 well tolerated; common adverse events: purpura/contusion, thrombocytopenia, neutropenia.","Company plans to initiate pivotal, registration-directed trial(s) for NX-5948 in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000086","json":"https://secwatch.observer/filing/0001549595-24-000086.json","markdown":"https://secwatch.observer/filing/0001549595-24-000086.md","text":"https://secwatch.observer/filing/0001549595-24-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000086/0001549595-24-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000086/nrix-20240616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:05:52.704565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}